158 related articles for article (PubMed ID: 27152946)
1. Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and α-Mangostin.
Xia Y; Li Y; Westover KD; Sun J; Chen H; Zhang J; Fisher DE
PLoS One; 2016; 11(5):e0155217. PubMed ID: 27152946
[TBL] [Abstract][Full Text] [Related]
2. α-Mangostin, a Natural Agent, Enhances the Response of NRAS Mutant Melanoma to Retinoic Acid.
Xia Y; Chen J; Gong C; Chen H; Sun J
Med Sci Monit; 2016 Apr; 22():1360-7. PubMed ID: 27104669
[TBL] [Abstract][Full Text] [Related]
3. Alpha mangostin Inhibits Hepatic Stellate Cells Activation Through TGF-β/Smad and Akt Signaling Pathways: An in vitro Study in LX2.
Rahmaniah R; Yuyuntia Y; Soetikno V; Arozal W; Antarianto RD; Louisa M
Drug Res (Stuttg); 2018 Mar; 68(3):153-158. PubMed ID: 28992660
[TBL] [Abstract][Full Text] [Related]
4. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
[TBL] [Abstract][Full Text] [Related]
5. NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.
Kießling MK; Nicolay JP; Schlör T; Klemke CD; Süss D; Krammer PH; Gülow K
Oncotarget; 2017 Jul; 8(28):45687-45697. PubMed ID: 28537899
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the AKT/mTOR Pathway Augments the Anticancer Effects of Sorafenib in Thyroid Cancer.
Yi H; Ye X; Long B; Ye T; Zhang L; Yan F; Yang Y; Li L
Cancer Biother Radiopharm; 2017 Jun; 32(5):176-183. PubMed ID: 28622037
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells.
Giovannetti E; Labots M; Dekker H; Galvani E; Lind JS; Sciarrillo R; Honeywell R; Smit EF; Verheul HM; Peters GJ
Curr Pharm Des; 2013; 19(5):927-39. PubMed ID: 22973961
[TBL] [Abstract][Full Text] [Related]
8. Synergistic inhibition of cell proliferation by combined targeting with kinase inhibitors and dietary xanthone is a promising strategy for melanoma treatment.
Xia Y; Sun J
Clin Exp Dermatol; 2018 Mar; 43(2):149-157. PubMed ID: 29168273
[TBL] [Abstract][Full Text] [Related]
9. Fluvastatin enhances sorafenib cytotoxicity in melanoma cells via modulation of AKT and JNK signaling pathways.
Zhang S; Doudican NA; Quay E; Orlow SJ
Anticancer Res; 2011 Oct; 31(10):3259-65. PubMed ID: 21965734
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of autophagy enhances the targeted therapeutic effect of sorafenib in thyroid cancer.
Yi H; Ye T; Ge M; Yang M; Zhang L; Jin S; Ye X; Long B; Li L
Oncol Rep; 2018 Feb; 39(2):711-720. PubMed ID: 29207150
[TBL] [Abstract][Full Text] [Related]
11. Convection-enhanced delivery of sorafenib and suppression of tumor progression in a murine model of brain melanoma through the inhibition of signal transducer and activator of transcription 3.
Zou Z; Yin Y; Lin J; Hsu LC; Brandon VL; Yang F; Jove R; Jandial R; Li G; Chen MY
J Neurosurg; 2016 May; 124(5):1310-8. PubMed ID: 26544779
[TBL] [Abstract][Full Text] [Related]
12. Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib.
Ishijima N; Kanki K; Shimizu H; Shiota G
Cancer Sci; 2015 May; 106(5):567-75. PubMed ID: 25683251
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Autophagy by Chloroquine Enhances the Antitumor Efficacy of Sorafenib in Glioblastoma.
Liu X; Sun K; Wang H; Dai Y
Cell Mol Neurobiol; 2016 Oct; 36(7):1197-208. PubMed ID: 26971793
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
[TBL] [Abstract][Full Text] [Related]
15. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
Locatelli SL; Giacomini A; Guidetti A; Cleris L; Mortarini R; Anichini A; Gianni AM; Carlo-Stella C
Leukemia; 2013 Aug; 27(8):1677-87. PubMed ID: 23360848
[TBL] [Abstract][Full Text] [Related]
16. Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
D'Alessandro R; Refolo MG; Lippolis C; Carella N; Messa C; Cavallini A; Carr BI
Cell Oncol (Dordr); 2018 Jun; 41(3):283-296. PubMed ID: 29470830
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of autophagy augments the anticancer activity of α-mangostin in chronic myeloid leukemia cells.
Chen JJ; Long ZJ; Xu DF; Xiao RZ; Liu LL; Xu ZF; Qiu SX; Lin DJ; Liu Q
Leuk Lymphoma; 2014 Mar; 55(3):628-38. PubMed ID: 23734655
[TBL] [Abstract][Full Text] [Related]
18. Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma.
Pal HC; Diamond AC; Strickland LR; Kappes JC; Katiyar SK; Elmets CA; Athar M; Afaq F
Oncotarget; 2016 Jan; 7(2):1227-41. PubMed ID: 26517521
[TBL] [Abstract][Full Text] [Related]
19. Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.
Yokoi K; Kobayashi A; Motoyama H; Kitazawa M; Shimizu A; Notake T; Yokoyama T; Matsumura T; Takeoka M; Miyagawa SI
Oncol Rep; 2018 Feb; 39(2):843-850. PubMed ID: 29251327
[TBL] [Abstract][Full Text] [Related]
20. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
Lu M; Fei Z; Zhang G
Biomed Pharmacother; 2018 Jan; 97():1282-1288. PubMed ID: 29156516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
